<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22385" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Graft-Versus-Host Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Justiz Vaillant</surname>
            <given-names>Angel A.</given-names>
          </name>
          <aff>University of the West Indies</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Modi</surname>
            <given-names>Pranav</given-names>
          </name>
          <aff>DY Patil Hospital, Navi Mumbai, India</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mohammadi</surname>
            <given-names>Oranus</given-names>
          </name>
          <aff>Aventura Hospital and Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Angel Justiz Vaillant declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pranav Modi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Oranus Mohammadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>6</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22385.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Graft-versus-host disease (GVHD) is a severe complication that can occur following hematopoietic stem cell transplantation. This condition arises when immunocompetent T lymphocytes from the donor graft recognize the recipient's tissues as foreign due to histocompatibility differences and initiate an immune response against them. This attack typically occurs within the first 100 days posttransplant, leading to tissue damage in various organs, including the skin, gastrointestinal tract, liver, and lungs. GVHD can manifest as acute or chronic forms, each with distinct clinical presentations and management strategies.</p>
        <p>This activity provides an in-depth exploration of GVHD, focusing on its pathophysiology, clinical manifestations, diagnosis, and management. Participants gain a deeper understanding of how to recognize and evaluate GVHD, as well as the role of the interprofessional team in its management. This activity also addresses the importance of interdisciplinary collaboration in optimizing treatment plans and providing comprehensive care for GVHD patients, highlighting the significance of timely interventions in improving outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Implement prophylactic measures, including immunosuppressive medications and T-cell depletion techniques, to mitigate the risk of GVHD development post-transplantation.</p></list-item><list-item><p>Differentiate between acute and chronic graft-versus-host disease based on their clinical presentations and timing of onset.</p></list-item><list-item><p>Apply immunosuppressive therapies, such as corticosteroids, calcineurin inhibitors, and monoclonal antibodies, tailored to the severity and subtype of graft-versus-host disease.</p></list-item><list-item><p>Collaborate with multidisciplinary teams, including hematologists, oncologists, dermatologists, gastroenterologists, and transplant specialists, to develop comprehensive graft-versus-host disease management plans.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22385&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22385">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22385.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Graft-versus-host disease (GVHD) is a systemic disorder occurring when immune cells from transplanted tissue recognize the recipient's body as foreign and attack&#x000a0;its cells. In this context, graft refers to transplanted or donated tissue,&#x000a0;while&#x000a0;host refers to the recipient's tissues.&#x000a0;GVHD is a common complication&#x000a0;following allogeneic hematopoietic stem cell transplant.<xref ref-type="bibr" rid="article-22385.r1">[1]</xref></p>
        <p>GVHD has traditionally&#x000a0;been categorized&#x000a0;based on the timing of presentation into acute and chronic, with a cutoff of 100 days post-transplant. These classifications have been further&#x000a0;refined based on clinical manifestations accepted by the National Institutes of Health (NIH):</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Acute classic GVHD</bold> presents within 100 days of transplantation with&#x000a0;typical clinical features of acute GVHD.</p>
          </list-item>
          <list-item>
            <p><bold>Persistent, recurrent, or late-onset acute GVHD </bold>manifests with clinical features of classic acute GVHD but after 100 days of transplantation.</p>
          </list-item>
          <list-item>
            <p><bold>Classic chronic GVHD</bold> presents after 100 days of transplant with classic clinical features of chronic GVHD.</p>
          </list-item>
          <list-item>
            <p><bold>Overlap syndrome</bold> may&#x000a0;occur at any time posttransplant with features of both acute and chronic GVHD.<xref ref-type="bibr" rid="article-22385.r1">[1]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22385.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>GVHD arises from a complex interplay of immunological factors during allogeneic transplantation. The etiology of GVHD involves the recognition of recipient tissues as foreign by donor immune cells, leading to an immune-mediated attack on the host. GVHD occurs in the following settings:</p>
        <list list-type="bullet">
          <list-item>
            <p>Following allogeneic bone transplantation (most common)</p>
          </list-item>
          <list-item>
            <p>Following transplantation of solid organs that are rich in lymphoid cells (eg&#x000a0;liver)</p>
          </list-item>
          <list-item>
            <p>Following transfusion of nonirradiated blood</p>
          </list-item>
        </list>
        <p>For GVHD to occur, immunologically competent cells should&#x000a0;be transplanted&#x000a0;into immunodeficient recipients, and these transferred cells should recognize alloantigens in the host. Other important factors that determine&#x000a0;the occurrence and severity of GVHD include:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Donor-host factors:&#x000a0;</bold>The incidence of GVHD increases with unmatched donor transplants, human leukocyte antigen (HLA) disparity, and sex mismatching.</p>
          </list-item>
          <list-item>
            <p><bold>Stem-cell source factors:&#x000a0;</bold>Cryopreservation of marrow&#x000a0;before&#x000a0;infusion and the use of umbilical cord blood&#x000a0;decrease&#x000a0;the incidence of GVHD.</p>
          </list-item>
          <list-item>
            <p><bold>Immune modulation factors</bold>: The incidence of GVHD is lower with triple therapy (cyclosporine, methotrexate [MTX], and prednisone) as compared with double therapy (cyclosporine and MTX).<xref ref-type="bibr" rid="article-22385.r2">[2]</xref>&#x000a0;In preclinical settings, statins can inhibit antigen-presenting cells (APC) function and reduce the expression of major histocompatibility complex (MHC) class II.<xref ref-type="bibr" rid="article-22385.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Chemotherapy and radiation therapy</bold>: High-dose chemotherapy causes local tissue damage and increases circulating cytokine levels, leading to a cytokine storm; this increases the ability of immune cells in the graft to recognize host antigens. Regimens, including total body irradiation, are associated with increased incidence and severity of GVHD compared to chemotherapy alone.<xref ref-type="bibr" rid="article-22385.r4">[4]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22385.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Acute GVHD can occur in up to 50% of patients receiving hematopoietic stem cell transplantation from an HLA-matched sibling.<xref ref-type="bibr" rid="article-22385.r5">[5]</xref><xref ref-type="bibr" rid="article-22385.r6">[6]</xref>&#x000a0;The occurrence is typically higher in unmatched donors. The incidence of chronic GVHD ranges from 6% to 80%.<xref ref-type="bibr" rid="article-22385.r7">[7]</xref>&#x000a0;GVHD is considered one of the&#x000a0;main&#x000a0;causes of morbidity and mortality after hematopoietic stem cell transplantation; more than 10% of patients will die from this complication.<xref ref-type="bibr" rid="article-22385.r8">[8]</xref></p>
        <p>Risk factors&#x000a0;for acute GVHD&#x000a0;include higher degrees of HLA mismatch, prior acute GVHD sex disparity, older age of the donor or recipient, peripheral stem cell recipients, alloimmunization of the donor, cytomegalovirus and Epstein Barr virus seropositivity.<xref ref-type="bibr" rid="article-22385.r9">[9]</xref>&#x000a0;These factors collectively contribute to the increased risk of developing acute GVHD following hematopoietic stem cell transplantation.</p>
      </sec>
      <sec id="article-22385.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The immune system's cells&#x000a0;are trained&#x000a0;early to differentiate between self and&#x000a0;nonself&#x000a0;cells. The ability to recognize nonself cells depends on the histocompatibility genes, which provide instructions for making a group of related proteins known as&#x000a0;major histocompatibility complex (MHC) proteins or HLA.</p>
        <p>The histocompatibility genes code for MHC class I proteins on all nucleated cells in the body, and MHC class II molecules are expressed only on APC. During transplantation, the&#x000a0;donor tissue, usually obtained from a genetically different individual (an allograft), prompts immune cells in the graft to recognize the recipient's MHC proteins as nonself, triggering an immune response between the donor and the recipient.</p>
        <p>Donor cytotoxic CD8 T-cells recognize host tissue as foreign and proliferate to cause severe organ damage (type IV cytotoxic T-cell hypersensitivity reaction). Donor allograft T-cells are the primary effector cells for GVHD, and its pathogenesis can be divided into&#x000a0;3 phases (see&#x000a0;<bold>Image.</bold>&#x000a0;GVHD Pathogenesis).</p>
        <list list-type="bullet">
          <list-item>
            <p>Phase 1 (afferent phase): Radiation or chemotherapy before bone marrow transplantation damages recipient tissue,&#x000a0;leading to increased levels of inflammatory cytokines and the expression of MHC antigens; this enhances the APC's ability to present alloantigens to the donor T-cells.</p>
          </list-item>
          <list-item>
            <p>Phase 2 (efferent phase): This phase&#x000a0;is characterized&#x000a0;by the interaction of donor T-cells with host APC, leading to their proliferating and differentiation into activated T cells, which release additional inflammatory cytokines.</p>
          </list-item>
          <list-item>
            <p>Phase 3 (effector phase): The third phase&#x000a0;is characterized&#x000a0;by migrating cytotoxic T lymphocytes and natural killer cells to target organs, causing tissue damage and leading to multiorgan failure.<xref ref-type="bibr" rid="article-22385.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>GVHD is a complication that can occur after a stem cell or bone marrow transplant, where the donor's immune cells attack the recipient's tissues; it is a complex process involving multiple cytokines and immune cells. Some critical cytokines involved in the etiopathogenesis of GVHD include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Interleukin-2 (IL-2) plays a crucial role in the activation and proliferation of T cells, central to the immune response involved in GVHD.</p>
          </list-item>
          <list-item>
            <p>Activated T-cells and macrophages produce tumor necrosis factor-alpha (TNF-&#x003b1;), promoting inflammation and tissue damage in GVHD.</p>
          </list-item>
          <list-item>
            <p>Interleukin-1 (IL-1), similar to TNF-&#x003b1;, is a proinflammatory cytokine produced by activated immune cells that contribute to tissue damage and inflammation.</p>
          </list-item>
          <list-item>
            <p>Interleukin-6 (IL-6) is another proinflammatory cytokine involved in the pathogenesis of GVHD. IL-6 promotes B-cell activation and differentiation, as well as inflammatory responses.</p>
          </list-item>
          <list-item>
            <p>Interleukin-12 (IL-12), produced by APC, stimulates the differentiation of naive T cells into Th1 cells, which are involved in cell-mediated immune responses associated with GVHD.</p>
          </list-item>
          <list-item>
            <p>Interleukin-17 (IL-17), mainly produced by Th17 cells, promotes inflammation and tissue damage in GVHD, particularly in the gut.</p>
          </list-item>
          <list-item>
            <p>Interferon-gamma (IFN-&#x003b3;), secreted by activated T-cells, is involved in the inflammatory response and tissue damage characteristic of GVHD.</p>
          </list-item>
          <list-item>
            <p>Transforming growth factor-beta (TGF-&#x003b2;) can have both pro- and anti-inflammatory effects; however, it generally has&#x000a0;immunosuppressive properties in GVHD, regulating T-cell differentiation and function.</p>
          </list-item>
        </list>
        <p>These cytokines are among many not listed, and they interact in a complex network to drive the pathogenesis of GVHD,&#x000a0;resulting&#x000a0;in tissue damage and systemic inflammation. Therapeutic strategies for GVHD often target these cytokines to modulate the immune response and mitigate disease severity.<xref ref-type="bibr" rid="article-22385.r11">[11]</xref><xref ref-type="bibr" rid="article-22385.r12">[12]</xref></p>
      </sec>
      <sec id="article-22385.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>In the gastrointestinal (GI) tract, apoptosis of epithelial cells is the most&#x000a0;important&#x000a0;feature. Dilated crypts, crypt destruction, villus atrophy, and neutrophilic infiltration can also&#x000a0;be observed&#x000a0;in small bowel specimens.<xref ref-type="bibr" rid="article-22385.r13">[13]</xref>&#x000a0;A liver biopsy typically shows dysmorphic small bile ducts with portal inflammation. Histopathological damage of the skin ranges from minimal vacuolization to separation of the dermis from the epidermis.&#x000a0;Grades of skin&#x000a0;GVHD are as follows (see&#x000a0;<bold>Image.</bold>&#x000a0;Grades of&#x000a0;Skin Graft-Versus-Host&#x000a0;Disease):</p>
        <list list-type="bullet">
          <list-item>
            <p>Grade I: Minimal vacuolization in the epidermis</p>
          </list-item>
          <list-item>
            <p>Grade II: Vacuolization and dyskeratotic bodies</p>
          </list-item>
          <list-item>
            <p>Grade III: Subepidermal cleft formation</p>
          </list-item>
          <list-item>
            <p>Grade IV: Separation of the dermis from the epidermis&#x000a0;<xref ref-type="bibr" rid="article-22385.r14">[14]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22385.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Acute GVHD usually involves the skin,&#x000a0;gastrointestinal (GI) tract, and liver; this condition occurs in 70%, 74%, and 44% of cases, respectively. GVHD can also affect the lungs, kidneys, eyes, and hematopoietic system and may decrease responsiveness to active immunization.&#x000a0;</p>
        <p>The most common skin manifestation is a pruritic or painful maculopapular rash that initially involves the neck's palms, soles, shoulders, and nape.&#x000a0;This rash can spread diffusely and become confluent. In severe GVHD, bullous lesions&#x000a0;resembling&#x000a0;toxic epidermal necrolysis (TEN) can develop.</p>
        <p>GI symptoms most commonly include diarrhea and abdominal pain, but mucositis, mucosal ulceration, nausea, and vomiting can also occur. Diarrhea is secretory and continues despite fasting. Initially watery, diarrhea may progress to become bloody, potentially requiring frequent blood transfusions and causing difficulty in maintaining adequate fluid balance.&#x000a0;</p>
        <p>Liver involvement usually presents together with either cutaneous or&#x000a0;GI manifestations; it rarely occurs in isolation. Abnormal liver function tests are characteristic, typically&#x000a0;showing&#x000a0;elevated bilirubin and alkaline phosphatase levels. Coagulopathy and hyperammonemia are rare but can occur in severe forms. Hepatomegaly, as well as pale urine and stool, may be present.&#x000a0;</p>
        <p>Chronic GVHD shares&#x000a0;many features with collagen vascular disorders and systemic sclerosis.<xref ref-type="bibr" rid="article-22385.r15">[15]</xref>&#x000a0;In the oral cavity, this condition may present as lichen planus with a risk of&#x000a0;developing into&#x000a0;oral squamous cell carcinoma, which differs from classical pathology and&#x000a0;appears&#x000a0;more aggressive in patients with stem cell transplantation.<xref ref-type="bibr" rid="article-22385.r16">[16]</xref>&#x000a0;Recurrent infections can be a cause of death, often complicating immunosuppression.<xref ref-type="bibr" rid="article-22385.r17">[17]</xref><xref ref-type="bibr" rid="article-22385.r18">[18]</xref>&#x000a0;Ocular involvement indicates poor prognosis in GVHD, usually affecting the ocular surface and manifesting with dry eye or keratoconjunctivitis sicca.<xref ref-type="bibr" rid="article-22385.r19">[19]</xref></p>
      </sec>
      <sec id="article-22385.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnosis is usually clinical. Traditionally, the criteria as described by Billingham include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Immunologically competent cells must be present in the graft.</p>
          </list-item>
          <list-item>
            <p>The recipient should have transplantation alloantigens that appear foreign to the graft and can, therefore, stimulate it antigenically.</p>
          </list-item>
          <list-item>
            <p>The&#x000a0;recipient should not be capable&#x000a0;of mounting an effective immunologic reaction against the graft, or there must be enough&#x000a0;time for the graft to&#x000a0;manifest&#x000a0;an immune response.<xref ref-type="bibr" rid="article-22385.r20">[20]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>All patients who&#x000a0;undergo hematopoietic cell transplantation are at risk of GVHD, although&#x000a0;it usually occurs during the first few months posttransplantation.<xref ref-type="bibr" rid="article-22385.r21">[21]</xref>&#x000a0;Skin and&#x000a0;GI (usually rectal) biopsies can help confirm the diagnosis. The staging of the disease&#x000a0;is based&#x000a0;on the extent of symptoms and lab abnormalities.</p>
        <p>The use of biomarkers for the diagnosis and prognosis estimation is an area of investigation. No biomarker is ready for clinical application yet.<xref ref-type="bibr" rid="article-22385.r22">[22]</xref><xref ref-type="bibr" rid="article-22385.r23">[23]</xref><xref ref-type="bibr" rid="article-22385.r24">[24]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-22385.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>All patients receiving hematopoietic cell transplantation should undergo prophylactic treatment for GVHD. Treatment protocols differ by institution, but a combination of cyclosporine and&#x000a0;MTX&#x000a0;is usually continued&#x000a0;for several months posttransplantation. Antibacterial, antiviral, and antifungal prophylaxis&#x000a0;are typically added&#x000a0;posttreatment to mitigate the risk of infections.&#x000a0;</p>
        <p>Treatment for GVHD depends on the severity of symptoms and the organs involved. Most treatment options focus on immunosuppression of donor T-cells, but they must be balanced to reduce the GVHD symptoms while avoiding decreasing the beneficial graft versus tumor (GVT) response. Corticosteroids remain the most commonly used treatment.</p>
        <p>Grade 1 GVHD&#x000a0;is usually managed&#x000a0;with topical steroids to control local symptoms. Topical tacrolimus is an option for steroid-resistant disease. &#x000a0;Grade 2 or higher GVHD requires the addition of systemic steroids, most commonly methylprednisolone 2 mg/kg/day in divided doses. In cases of&#x000a0;GI involvement, adding a nonabsorbable corticosteroid (budesonide or beclomethasone) is more effective than systemic treatment alone. Steroids should&#x000a0;be avoided&#x000a0;if a&#x000a0;GI infection is present.&#x000a0;</p>
        <p>Gradual tapering of the steroid over several months is essential to prevent a GVHD flare. Patients with chronic GVHD will typically require prolonged courses of steroids, generally 2 to 3 years, and some patients may require lifelong treatment. Octreotide can&#x000a0;be added&#x000a0;in an attempt to decrease the amount of diarrhea.&#x000a0;</p>
        <p>Other agents that can&#x000a0;be added&#x000a0;to steroids include mycophenolate, etanercept, pentostatin, monoclonal antibodies, sirolimus, alpha-1-antitrypsin, mesenchymal stromal cells, and extracorporeal photopheresis.&#x000a0;However, their efficacy&#x000a0;is unclear.&#x000a0;Cyclosporine can&#x000a0;be added&#x000a0;to the treatment regimen for chronic GVHD in an attempt to decrease steroid dosage and duration.&#x000a0;This agent is often used in combination with steroids to provide a more comprehensive immunosuppressive effect.</p>
      </sec>
      <sec id="article-22385.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis&#x000a0;for GVHD depends on the clinical manifestations observed in the patient. These include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Skin:&#x000a0;Drug reactions, viral exanthems, radiation dermatitis</p>
          </list-item>
          <list-item>
            <p>Hepatic:&#x000a0;Infection, especially viral hepatitis, drug-induced liver injury, shock liver, immunotherapy-related hepatotoxicity, sinusoidal obstructive syndrome, malignancy&#x000a0;<xref ref-type="bibr" rid="article-22385.r25">[25]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal:
<list list-type="bullet"><list-item><p>Diarrhea: Iatrogenic (secondary to chemotherapy, immunosuppressants, antibiotics, or magnesium), infectious (CMV, EBV, adenovirus, rotavirus,&#x000a0;<italic toggle="yes">Clostridium&#x000a0;difficile</italic>, Mycobacterium&#x000a0;avium&#x000a0;complex, Giardia, Cryptosporidium), thrombotic microangiopathy, bile-salt malabsorption</p></list-item><list-item><p>Nausea and vomiting, anorexia: Iatrogenic (secondary to chemotherapy, immunosuppressants, radiation, antibiotics, or opioids)<xref ref-type="bibr" rid="article-22385.r26">[26]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22385.s11" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <p>GVHD occurs when transplanted donor cells recognize the recipient's tissues as foreign and attack them, leading to a range of symptoms affecting the skin,&#x000a0;GI tract, liver, and other organs. Treatment typically involves a combination of medications and supportive care measures. An overview of common treatments is as follows:</p>
        <p><bold>Immunosuppressive medications&#x000a0;</bold>are the cornerstone of GVHD treatment, suppressing the immune system to prevent it from attacking the recipient's tissues. Common immunosuppressants include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Corticosteroids: Prednisone and methylprednisolone&#x000a0;are often used&#x000a0;initially to reduce inflammation and suppress immune activity.</p>
          </list-item>
          <list-item>
            <p>Calcineurin inhibitors: Drugs like cyclosporine and tacrolimus&#x000a0;are frequently used&#x000a0;in combination with steroids to control GVHD.</p>
          </list-item>
          <list-item>
            <p>Other immunosuppressants: Mycophenolate mofetil, sirolimus, and azathioprine may also be used alone or in combination with other medications.</p>
          </list-item>
        </list>
        <p><bold>Antithymocyte globulin&#x000a0;</bold>may be used to suppress the immune system in severe cases of GVHD, particularly in patients who do not respond to initial treatments. This medication targets T-cells, reducing their activity and helping to control GVHD symptoms.</p>
        <p><bold>Biological therapies</bold>&#x000a0;can target specific components of the immune system involved in GVHD. Examples include:</p>
        <list list-type="bullet">
          <list-item>
            <p>TNF inhibitors: Drugs like infliximab and etanercept may&#x000a0;be used&#x000a0;to treat severe&#x000a0;GI GVHD.</p>
          </list-item>
          <list-item>
            <p>IL-2&#x000a0;receptor antibodies: Agents like basiliximab and daclizumab can help suppress the immune response in GVHD.</p>
          </list-item>
        </list>
        <p><bold>Photopheresis&#x000a0;</bold>involves removing white blood cells from the patient's blood, treating them with a photosensitizing agent, exposing them to ultraviolet light, and returning them to the patient.&#x000a0;This&#x000a0;process can modulate the immune response and&#x000a0;is often used&#x000a0;in chronic GVHD cases.</p>
        <p><bold>Topical treatments</bold>&#x000a0;may&#x000a0;be used&#x000a0;for skin involvement in GVHD. Topical corticosteroids, moisturizers, and other supportive measures may relieve symptoms and promote healing.</p>
        <p><bold>Supportive care</bold>&#x000a0;includes managing symptoms and complications associated with GVHD, such as infections, nutritional deficiencies, and electrolyte imbalances.</p>
        <p><bold>Stem cell transplant modification&#x000a0;</bold>(using stem cells from a different donor) may&#x000a0;be considered&#x000a0;to reduce the risk or severity of GVHD in future transplants.</p>
        <p>Treatment decisions depend on various factors, including the severity of GVHD, the organs affected, the patient's overall health, and previous treatments. Close monitoring and collaboration between transplant specialists, oncologists, and other healthcare providers are essential for managing GVHD effectively.</p>
      </sec>
      <sec id="article-22385.s12" sec-type="Staging">
        <title>Staging</title>
        <p>The&#x000a0;2&#x000a0;most famous systems for acute GVHD staging are the International Cone Marrow Transplant Registry (IBMTR) system (A to D) and Glucksberg grade (1 to 4).<xref ref-type="bibr" rid="article-22385.r27">[27]</xref><xref ref-type="bibr" rid="article-22385.r28">[28]</xref>&#x000a0;Staging&#x000a0;is based&#x000a0;on clinical manifestations and severity of organ involvement.<xref ref-type="bibr" rid="article-22385.r6">[6]</xref></p>
        <p>
<bold>Skin&#x000a0; &#x000a0; &#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage 1: Maculopapular rash &#x0003c;25% of the body</p>
          </list-item>
          <list-item>
            <p>Stage 2:&#x000a0;Maculopapular rash 25% to 50% of the body</p>
          </list-item>
          <list-item>
            <p>Stage 3: Generalized erythroderma</p>
          </list-item>
          <list-item>
            <p>Stage 4: Generalized erythroderma with bullae</p>
          </list-item>
        </list>
        <p>
<bold>Liver</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage 1: Bilirubin 2 to 3, AST 150 to 750</p>
          </list-item>
          <list-item>
            <p>Stage 2: Bilirubin 3 to 6</p>
          </list-item>
          <list-item>
            <p>Stage 3: Bilirubin 6 to 15</p>
          </list-item>
          <list-item>
            <p>Stage 4: Bilirubin &#x0003e;15</p>
          </list-item>
        </list>
        <p>
<bold>Gastrointestinal&#x000a0;System</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage 1: Diarrhea &#x0003e;500 cc/day</p>
          </list-item>
          <list-item>
            <p>Stage 2: Diarrhea &#x0003e;1000 cc/day</p>
          </list-item>
          <list-item>
            <p>Stage 3: Diarrhea &#x0003e;1500 cc/day</p>
          </list-item>
          <list-item>
            <p>Stage 4: Diarrhea &#x0003e;2000 cc/day or severe abdominal pain</p>
          </list-item>
        </list>
        <p>
<bold>Glucksberg Grade:&#x000a0;</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Mild: No liver or&#x000a0;GI involvement, stage 1 to 2 skin involvement</p>
          </list-item>
          <list-item>
            <p>Moderate: Stage 1 liver or&#x000a0;GI involvement, stage 1 to 3 skin involvement</p>
          </list-item>
          <list-item>
            <p>Severe: Stage 2 to 3 skin, liver, or&#x000a0;GI involvement</p>
          </list-item>
          <list-item>
            <p>Life-threatening: stage 2 to 4 liver or&#x000a0;GI involvement, stage 1 to 4 skin involvement&#x000a0;<xref ref-type="bibr" rid="article-22385.r28">[28]</xref></p>
          </list-item>
        </list>
        <p>
<bold>International Cone Marrow Transplant Registry Severity Index:</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Mild: No liver or&#x000a0;GI involvement, stage 1 skin involvement</p>
          </list-item>
          <list-item>
            <p>Moderate: Stage 1 to 2 liver or GI involvement, stage 2 skin involvement</p>
          </list-item>
          <list-item>
            <p>Severe: Stage 3 skin, liver, or GI involvement</p>
          </list-item>
          <list-item>
            <p>Life-threatening: Stage 4&#x000a0;skin, liver, or GI involvement&#x000a0;<xref ref-type="bibr" rid="article-22385.r28">[28]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22385.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Mortality is generally higher in moderate to severe GVHD compared&#x000a0;to mild disease.<xref ref-type="bibr" rid="article-22385.r8">[8]</xref><xref ref-type="bibr" rid="article-22385.r29">[29]</xref>&#x000a0;The 5-year survival rate&#x000a0;for grade C is 25%,&#x000a0;and 5% for grade 4.<xref ref-type="bibr" rid="article-22385.r30">[30]</xref>&#x000a0;There is a strong correlation between the response to first-line treatment and survival.<xref ref-type="bibr" rid="article-22385.r6">[6]</xref>&#x000a0;Extensive skin involvement, diarrhea, thrombocytopenia, elevated liver enzymes, and lung or liver involvement&#x000a0;are poor prognostic factors for acute or chronic GVHD.<xref ref-type="bibr" rid="article-22385.r1">[1]</xref><xref ref-type="bibr" rid="article-22385.r31">[31]</xref>&#x000a0;Early recognition and aggressive management of these factors are crucial for improving patient outcomes.</p>
      </sec>
      <sec id="article-22385.s14" sec-type="Complications">
        <title>Complications</title>
        <p>GVHD is a complication of allogeneic hematopoietic stem cell transplant that can&#x000a0;lead to other&#x000a0;complications, including bronchiolitis obliterans syndrome, interstitial lung disease, obliterative bronchiolitis, organizing pneumonia, and pleuroparenchymal fibroelastosis.<xref ref-type="bibr" rid="article-22385.r32">[32]</xref>&#x000a0;These additional complications further contribute to morbidity and mortality in transplant recipients.</p>
        <p>Reported&#x000a0;complications include&#x000a0;GI involvement, resulting in fibrosis, motility abnormalities, and malabsorption. Lung problems may cause bronchiectasis, while infections&#x000a0;are common and can be fatal.&#x000a0;Liver complications include endothelialitis, bile duct destruction, and pericholangitis, but a liver biopsy&#x000a0;is not routinely performed&#x000a0;due to associated thrombocytopenia.<xref ref-type="bibr" rid="article-22385.r5">[5]</xref>&#x000a0;Instead, liver function tests and imaging studies are often used to assess liver involvement in GVHD.</p>
      </sec>
      <sec id="article-22385.s15" sec-type="Consultations">
        <title>Consultations</title>
        <p>Nutritionists should evaluate patients with GI involvement due to a higher risk of malnutrition and abnormalities in zinc, magnesium, vitamin B12, and vitamin D.<xref ref-type="bibr" rid="article-22385.r33">[33]</xref>&#x000a0;Nutritional support and supplementation are often necessary to address these deficiencies and optimize patient outcomes.</p>
      </sec>
      <sec id="article-22385.s16" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Along with timely, appropriate treatment and prophylactic measures, patients can receive counseling and education about remedial measures to improve the management of GVHD.</p>
        <list list-type="bullet">
          <list-item>
            <p>Skincare: The use of moisturizer, application of sunscreen lotion with an appropriate sun protection factor, avoidance of scratching on the sutured area or other regions, and wearing long sleeves and pants to protect the skin&#x000a0;are emphasized.</p>
          </list-item>
          <list-item>
            <p>Mouth care: Dental hygiene with topical fluorides is suggested.<xref ref-type="bibr" rid="article-22385.r34">[34]</xref></p>
          </list-item>
          <list-item>
            <p>Diet:&#x000a0;Avoiding substances that can cause loose stools, such as spicy food, is important. Patients should be cautious of the foods they choose to ingest.</p>
          </list-item>
          <list-item>
            <p>Hygiene:&#x000a0;Avoiding&#x000a0;infective sources, wearing a face and nose mask when going out, and keeping the hands and feet clean are essential for minimizing the risk of infections.</p>
          </list-item>
        </list>
        <p>All patients and caregivers should&#x000a0;receive vaccines against influenza and pneumococcus to reduce the risk of infection.<xref ref-type="bibr" rid="article-22385.r5">[5]</xref>&#x000a0;These vaccines are&#x000a0;crucial for protecting against serious respiratory illnesses.</p>
      </sec>
      <sec id="article-22385.s17" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key facts to keep in mind about GVHD include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>GVHD is when donor immune cells attack the recipient's tissues, often occurring after an allogeneic hematopoietic stem cell transplant.</p>
          </list-item>
          <list-item>
            <p>The typical clinical manifestations of acute and chronic GVHD include skin rash,&#x000a0;GI symptoms (such as diarrhea and abdominal pain), liver dysfunction, and involvement of other organs like the lungs.</p>
          </list-item>
          <list-item>
            <p>Staging and grading systems used for GVHD&#x000a0;include the IBMTR system and Glucksberg grade.</p>
          </list-item>
          <list-item>
            <p>Diagnostic criteria for GVHD&#x000a0;are primarily through clinical assessment.</p>
          </list-item>
          <list-item>
            <p>The principles of GVHD treatment include immunosuppressive medications, such as corticosteroids and calcineurin inhibitors, and agents, such as mycophenolate mofetil and sirolimus.</p>
          </list-item>
          <list-item>
            <p>Complications of GVHD are infections, hepatic dysfunction,&#x000a0;GI complications, and pulmonary complications like bronchiolitis obliterans syndrome.</p>
          </list-item>
          <list-item>
            <p>The prognosis of GVHD varies based on severity and response to treatment.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22385.s18" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Enhancing healthcare team outcomes for patients with GVHD involves several vital strategies. First, promoting interdisciplinary collaboration among healthcare professionals, including transplant specialists, hematologists, primary care providers, nurses, nutritionists, and pharmacists, ensures comprehensive care and holistic management of GVHD. Regular communication and information sharing among team members are crucial to ensure continuity of care and prompt response to patient needs. Ongoing education and training for healthcare professionals involved in GVHD care keep them updated on the latest treatment guidelines and best practices.</p>
        <p>Patient education is also essential. Educating patients and their families about GVHD, its symptoms, treatment options, and self-care strategies actively involve them in their care and promotes adherence to treatment plans. Care coordination strategies streamline care delivery, including scheduling appointments, coordinating treatments, and managing transitions between care settings. Establishing multidisciplinary clinics where patients receive integrated care from specialists in a single visit improves convenience and efficiency.</p>
        <p>Additionally, facilitating support groups for patients with GVHD and their caregivers provides emotional support, allows for sharing experiences, and promotes learning of coping strategies from one another. Participation in clinical trials and research studies is encouraged to advance the understanding and treatment of GVHD, promoting innovation in care delivery. By implementing these strategies, healthcare teams can optimize outcomes for patients with GVHD, improving quality of life and reducing the burden of this challenging condition.</p>
      </sec>
      <sec id="article-22385.s19">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22385&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22385">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/graft-versus-host-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22385">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22385/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22385">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-22385.s20">
        <fig id="article-22385.image.f1" position="float" orientation="portrait">
          <caption>
            <p>GVHD Pathogenesis&#x000a0; Reddy P, Ferrara JLM. Mouse models of graft-versus-host disease. Stembook Web site. https://www.stembook.org/node/54. Published February 28, 2009. Accessed March 12, 2024.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Three_phases_of_GVHD_immuno-biology" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22385.s21">
        <fig id="article-22385.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Grades of Skin Graft-Versus-Host Disease Ghimire S, Weber D, Mavin E, Wang XN, Dickinson AM, Ernst Holler E. Pathophysiology of GvHD and other HSCT-related major complications. <italic toggle="yes">Front Immunol.</italic>&#x000a0;2017;8:79. doi: 10.3389/fimmu.2017.00079.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Micrographs_of_grades_of_skin_graft-versus-host-disease" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-22385.s22">
        <title>References</title>
        <ref id="article-22385.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soci&#x000e9;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ritz</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Current issues in chronic graft-versus-host disease.</article-title>
            <source>Blood</source>
            <year>2014</year>
            <month>Jul</month>
            <day>17</day>
            <volume>124</volume>
            <issue>3</issue>
            <fpage>374</fpage>
            <page-range>374-84</page-range>
            <pub-id pub-id-type="pmid">24914139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antin</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Cutler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>VT</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Miklos</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Hochberg</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Alyea</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Soiffer</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation.</article-title>
            <source>Blood</source>
            <year>2003</year>
            <month>Sep</month>
            <day>01</day>
            <volume>102</volume>
            <issue>5</issue>
            <fpage>1601</fpage>
            <page-range>1601-5</page-range>
            <pub-id pub-id-type="pmid">12730113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shimabukuro-Vornhagen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liebig</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>von Bergwelt-Baildon</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Statins inhibit human APC function: implications for the treatment of GVHD.</article-title>
            <source>Blood</source>
            <year>2008</year>
            <month>Aug</month>
            <day>15</day>
            <volume>112</volume>
            <issue>4</issue>
            <fpage>1544</fpage>
            <page-range>1544-5</page-range>
            <pub-id pub-id-type="pmid">18684883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mielcarek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Leisenring</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Flowers</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Maloney</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Sandmaier</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Maris</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Storb</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.</article-title>
            <source>Blood</source>
            <year>2003</year>
            <month>Jul</month>
            <day>15</day>
            <volume>102</volume>
            <issue>2</issue>
            <fpage>756</fpage>
            <page-range>756-62</page-range>
            <pub-id pub-id-type="pmid">12663454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrara</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Holler</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Graft-versus-host disease.</article-title>
            <source>Lancet</source>
            <year>2009</year>
            <month>May</month>
            <day>02</day>
            <volume>373</volume>
            <issue>9674</issue>
            <fpage>1550</fpage>
            <page-range>1550-61</page-range>
            <pub-id pub-id-type="pmid">19282026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jamil</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Mineishi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>State-of-the-art acute and chronic GVHD treatment.</article-title>
            <source>Int J Hematol</source>
            <year>2015</year>
            <month>May</month>
            <volume>101</volume>
            <issue>5</issue>
            <fpage>452</fpage>
            <page-range>452-66</page-range>
            <pub-id pub-id-type="pmid">25864189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Atkinson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Gale</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>van Bekkum</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Gluckman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Good</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kolb</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Rimm</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ringd&#x000e9;n</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation.</article-title>
            <source>Blood</source>
            <year>1990</year>
            <month>Jun</month>
            <day>15</day>
            <volume>75</volume>
            <issue>12</issue>
            <fpage>2459</fpage>
            <page-range>2459-64</page-range>
            <pub-id pub-id-type="pmid">2350582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacMillan</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Robin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>DeFor</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Alousi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>VT</given-names>
              </name>
              <name>
                <surname>Bola&#x000f1;os-Meade</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ferrara</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blazar</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Holtan</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Jacobsohn</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pasquini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Socie</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Antin</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Weisdorf</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>761</fpage>
            <page-range>761-7</page-range>
            <pub-id pub-id-type="pmid">25585275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gale</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Bortin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>van Bekkum</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Biggs</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Dicke</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Gluckman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Good</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Kersey</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for acute graft-versus-host disease.</article-title>
            <source>Br J Haematol</source>
            <year>1987</year>
            <month>Dec</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>397</fpage>
            <page-range>397-406</page-range>
            <pub-id pub-id-type="pmid">3322360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nassereddine</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rafei</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Elbahesh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tabbara</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Acute Graft <italic>Versus</italic> Host Disease: A Comprehensive Review.</article-title>
            <source>Anticancer Res</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>1547</fpage>
            <page-range>1547-1555</page-range>
            <pub-id pub-id-type="pmid">28373413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elhage</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sligar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cuthbertson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sluyter</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Insights into mechanisms of graft-versus-host disease through humanised mouse models.</article-title>
            <source>Biosci Rep</source>
            <year>2022</year>
            <month>Sep</month>
            <day>30</day>
            <volume>42</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">35993192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>V&#x000e1;rady</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cserepes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>N&#x000e9;meth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Szab&#x000f3;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sarkadi</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Cell surface membrane proteins as personalized biomarkers: where we stand and where we are headed.</article-title>
            <source>Biomark Med</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>803</fpage>
            <page-range>803-19</page-range>
            <pub-id pub-id-type="pmid">24044572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salomao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dorritie</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mapara</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Sepulveda</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Histopathology of Graft-vs-Host Disease of Gastrointestinal Tract and Liver: &#x02009;An Update.</article-title>
            <source>Am J Clin Pathol</source>
            <year>2016</year>
            <month>May</month>
            <volume>145</volume>
            <issue>5</issue>
            <fpage>591</fpage>
            <page-range>591-603</page-range>
            <pub-id pub-id-type="pmid">27247365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghimire</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mavin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>XN</given-names>
              </name>
              <name>
                <surname>Dickinson</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Holler</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology of GvHD and Other HSCT-Related Major Complications.</article-title>
            <source>Front Immunol</source>
            <year>2017</year>
            <volume>8</volume>
            <fpage>79</fpage>
            <pub-id pub-id-type="pmid">28373870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Vogelsang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Flowers</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Chronic graft-versus-host disease.</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>215</fpage>
            <page-range>215-33</page-range>
            <pub-id pub-id-type="pmid">12720215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zadik</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zeevi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Miyazaki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Figueiredo</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Or</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Oral cancer in patients after hematopoietic stem-cell transplantation: long-term follow-up suggests an increased risk for recurrence.</article-title>
            <source>Transplantation</source>
            <year>2010</year>
            <month>Dec</month>
            <day>15</day>
            <volume>90</volume>
            <issue>11</issue>
            <fpage>1243</fpage>
            <page-range>1243-4</page-range>
            <pub-id pub-id-type="pmid">21119507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000e1;lvez</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vera</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Arce</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Vitiligo type cutaneous manifestation of chronic graft-versus-host disease. Case report.</article-title>
            <source>Rev Chil Pediatr</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>89</volume>
            <issue>1</issue>
            <fpage>113</fpage>
            <page-range>113-117</page-range>
            <pub-id pub-id-type="pmid">29664513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gandelman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Zic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dewan</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Flowers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cutler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pidala</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jagasia</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Tkaczyk</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>The Anatomic Distribution of Skin Involvement in Patients with Incident Chronic Graft-versus-Host Disease.</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>279</fpage>
            <page-range>279-286</page-range>
            <pub-id pub-id-type="pmid">30219700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munir</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Aylward</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A Review of Ocular Graft-Versus-Host Disease.</article-title>
            <source>Optom Vis Sci</source>
            <year>2017</year>
            <month>May</month>
            <volume>94</volume>
            <issue>5</issue>
            <fpage>545</fpage>
            <page-range>545-555</page-range>
            <pub-id pub-id-type="pmid">28422804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Billingham</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>The biology of graft-versus-host reactions.</article-title>
            <source>Harvey Lect</source>
            <string-date>1966-1967</string-date>
            <volume>62</volume>
            <fpage>21</fpage>
            <page-range>21-78</page-range>
            <pub-id pub-id-type="pmid">4875305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Firoz</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Nghiem</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Qureshi</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Role of skin biopsy to confirm suspected acute graft-vs-host disease: results of decision analysis.</article-title>
            <source>Arch Dermatol</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>142</volume>
            <issue>2</issue>
            <fpage>175</fpage>
            <page-range>175-82</page-range>
            <pub-id pub-id-type="pmid">16490845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vander Lugt</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Hanash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ritz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>VT</given-names>
              </name>
              <name>
                <surname>Antin</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Couriel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ferrara</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Paczesny</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Aug</month>
            <day>08</day>
            <volume>369</volume>
            <issue>6</issue>
            <fpage>529</fpage>
            <page-range>529-39</page-range>
            <pub-id pub-id-type="pmid">23924003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrara</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Greenson</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Holler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Teshima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Landfried</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Akashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vander Lugt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Hanash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paczesny</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.</article-title>
            <source>Blood</source>
            <year>2011</year>
            <month>Dec</month>
            <day>15</day>
            <volume>118</volume>
            <issue>25</issue>
            <fpage>6702</fpage>
            <page-range>6702-8</page-range>
            <pub-id pub-id-type="pmid">21979939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korngold</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marini</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>de Baca</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Giles-Komar</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses.</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2003</year>
            <month>May</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>292</fpage>
            <page-range>292-303</page-range>
            <pub-id pub-id-type="pmid">12766879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsukuma</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ramsamooj</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD).</article-title>
            <source>J Gastrointest Oncol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>Suppl 1</issue>
            <fpage>S21</fpage>
            <page-range>S21-31</page-range>
            <pub-id pub-id-type="pmid">27034810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naymagon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Naymagon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Renteria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Colombel</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Ferrara</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Acute graft-versus-host disease of the gut: considerations for the gastroenterologist.</article-title>
            <source>Nat Rev Gastroenterol Hepatol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>12</issue>
            <fpage>711</fpage>
            <page-range>711-726</page-range>
            <pub-id pub-id-type="pmid">28951581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glucksberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Storb</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fefer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buckner</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Neiman</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Clift</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Lerner</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.</article-title>
            <source>Transplantation</source>
            <year>1974</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>295</fpage>
            <page-range>295-304</page-range>
            <pub-id pub-id-type="pmid">4153799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rowlings</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Przepiorka</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Gale</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Passweg</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Henslee-Downey</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Cahn</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Calderwood</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gratwohl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soci&#x000e9;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abecasis</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Sobocinski</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade.</article-title>
            <source>Br J Haematol</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>97</volume>
            <issue>4</issue>
            <fpage>855</fpage>
            <page-range>855-64</page-range>
            <pub-id pub-id-type="pmid">9217189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cho</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barba</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Maloy</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Avecilla</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Castro-Malaspina</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Giralt</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Jakubowski</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Koehne</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Meagher</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>O'Reilly</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Papadopoulos</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Ponce</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Tamari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van den Brink</surname>
                <given-names>MRM</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Devlin</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Perales</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.</article-title>
            <source>Bone Marrow Transplant</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>52</volume>
            <issue>12</issue>
            <fpage>1629</fpage>
            <page-range>1629-1636</page-range>
            <pub-id pub-id-type="pmid">28991247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cahn</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Milpied</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Blaise</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Antin</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Leblond</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ifrah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jouet</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Loberiza</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ringden</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Soci&#x000e9;</surname>
                <given-names>G</given-names>
              </name>
              <collab>Soci&#x000e9;t&#x000e9; Fran&#x000e7;aise de Greffe de Mo&#x000eb;lle et Th&#x000e9;rapie Cellulaire</collab>
              <collab>Dana Farber Cancer Institute</collab>
              <collab>International Bone Marrow Transplant Registry</collab>
            </person-group>
            <article-title>Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Soci&#x000e9;t&#x000e9; Fran&#x000e7;aise de Greffe de Mo&#x000eb;lle et Th&#x000e9;rapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study.</article-title>
            <source>Blood</source>
            <year>2005</year>
            <month>Aug</month>
            <day>15</day>
            <volume>106</volume>
            <issue>4</issue>
            <fpage>1495</fpage>
            <page-range>1495-500</page-range>
            <pub-id pub-id-type="pmid">15878974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Zirafi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Roan</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>M&#x000fc;nch</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of EPI-X4 as a urinary peptide biomarker for diagnosis and prognosis of late acute GvHD.</article-title>
            <source>Bone Marrow Transplant</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>51</volume>
            <issue>8</issue>
            <fpage>1137</fpage>
            <page-range>1137-9</page-range>
            <pub-id pub-id-type="pmid">27042833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergeron</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Bronchiolitis Obliterans Syndrome and Other Late Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation.</article-title>
            <source>Clin Chest Med</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>607</fpage>
            <page-range>607-621</page-range>
            <pub-id pub-id-type="pmid">29128013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Meij</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>de Graaf</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wierdsma</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Langius</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>van Leeuwen</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Visser</surname>
                <given-names>OJ</given-names>
              </name>
            </person-group>
            <article-title>Nutritional support in patients with GVHD of the digestive tract: state of the art.</article-title>
            <source>Bone Marrow Transplant</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>48</volume>
            <issue>4</issue>
            <fpage>474</fpage>
            <page-range>474-82</page-range>
            <pub-id pub-id-type="pmid">22773121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22385.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mays</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Fassil</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Pavletic</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Bassim</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research.</article-title>
            <source>Oral Dis</source>
            <year>2013</year>
            <month>May</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>327</fpage>
            <page-range>327-46</page-range>
            <pub-id pub-id-type="pmid">23107104</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
